Modulation of protein-protein interactions with small molecules represents an emerging area of interest in drug discovery, enabling new therapeutic paradigms unprecedented with other drug classes such as catalytic enzyme inhibitors. Immunomodulatory or PROTAC drugs are a prime example for proximity-induced pharmacology where in the case of multiple myeloma, degradation of oncogenic transcription factors is achieved via recruitment of an E3 ligase complex. This project is part of the IMI EUbOPEN project.